Linagliptin (Rx)
Linagliptin Brand name: Tradjenta
Dea Class: Rx (Prescription drug)
Drug Class: Antidiabetics, Dipeptyl Peptidase-IV Inhibitors
Dosage form: Tablet 5mg
In this Post
What is Linagliptin and how does it work?
Linagliptin is oral DPP-4 inhibitor given once daily; reduces breakdown of GLP-1 which increases insulin secretion
Used in adults with type 2 diabetes mellitus; mean A1C reduction 0.7%
Used as monotherapy or in combination with other medications, with the exception of GLP-1 agonists
What are Linagliptin uses?
Linagliptin is used for adults with type 2 diabetes mellitus along with diet and exercise to lower blood sugar; may be used as monotherapy or in combination with other common antidiabetic medications including metformin, sulfonylurea, pioglitazone, or insulin
How should I take Linagliptin?
Linagliptin comes as a tablet to take by mouth. It is usually taken once a day with or without food. Take it at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take linagliptin exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Linagliptin helps to control high blood sugar but does not cure diabetes. Continue to take linagliptin even if you feel well. Do not stop taking it without talking to your doctor.
Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with Tradjenta and each time you refill your prescription.
Linagliptin Side Effects
Nasopharyngitis (4.3%)
Hyperlipidemia (2.8%; with pioglitazone)
Cough (2.4%; with metformin and sulfonylurea)
Hypertriglyceridemia (2.4%; with sulfonylurea)
Weight gain (2.3%; with pioglitazone)
Hypoglycemia
- 7.6% overall incidence
- 22.9% incidence compared with placebo plus metformin and a sulfonylurea
- Incidence similar to placebo with monotherapy or combined with metformin or pioglitazone
Acute pancreatitis, including fatal pancreatitis
Hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions
Severe and disabling arthralgia
Bullous pemphigoid
Rash
Mouth ulceration, stomatitis
Rhabdomyolysis
Heart failure
Hypoglycemia with concomitant use of insulin and insulin secretagogues
What Are Warnings and Precautions for Linagliptin?
Warnings
Use in combination with an insulin secretagogue (eg, sulfonylurea) was associated with a higher rate of hypoglycemia compared with placebo in a clinical trial; a lower dose of insulin secretagogue or insulin may be required to reduce risk of hypoglycemia when used in combination with this drug
Rifampin decreased Tradjenta exposure suggesting that the levels may be reduced when administered in combination with a strong P-gp or CYP 3A4 inducer; alternative treatment is strongly recommended when linagliptin is to be administered with P-gp or CYP 3A4 inducers
Serious hypersensitivity reactions reported including anaphylaxis, angioedema, and exfoliative skin conditions
Severe and disabling arthralgia reported in patients taking DPP-4 inhibitors; consider as a possible cause for severe joint pain and discontinue drug if appropriate
Heart failure has been observed with two other members of the DPP-4 inhibitor class; consider risks and benefits of empagliflozin in patients with risk factors for heart failure; monitor for signs and symptoms; if heart failure develops, manage accordingly to standard of care and consider interrupting treatment
Bullous pemphigoid reported with DPP-4 inhibitor use, which required hospitalization; in reported cases, patients recovered with topical or systemic immunosuppressive treatment and discontinuation of DPP-4 inhibitor; patients should report development blisters/erosions; discontinue DPP-4 therapy and consult a dermatologist if bullous pemphigoid suspected
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with therapy
Before taking Linagliptin, Cautions
Hypersensitivity (eg, anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity)
Type 1 diabetes mellitus
Diabetic ketoacidosis
Pregnancy and Lactation
Pregnancy
-
The limited data in pregnant women are not sufficient to inform of drug-associated risk for major birth defects and miscarriage; there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy
Lactation
- There is no information regarding presence of drug in human milk, the effects on breastfed infant, or effects on milk production
What Are Dosages of Linagliptin?
Dosage Forms & Strengths
Tablet 5mg
5 mg/day PO.
5 mg/day PO.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Not indicated.
Linagliptin brand name
Brand name: Tradjenta Tablet 5mg
Brand names of Linagliptin combination products
- Trijardy® (as a combination product containing Empagliflozin, Linagliptin, Metformin)
- Glyxambi® (containing Linagliptin, Empagliflozin)
- Jentadueto® (containing Linagliptin, Metformin)
-
(containing Empagliflozin, Linagliptin, Metformin)
Also Read
Glyburide Uses, Side Effects, Dosage, Brands
Glipizide Uses, Side Effects, Dosage, Brands
